Default company panoramic image
3c4d9b6f f6c0 4a41 a9fd 4510c30498ec

Non-Invasive Diagnostics, LLC

Non-invasive, radiation free breast cancer diagnostic device

  • Stage Not Set
  • Industry Medical Devices and Equipment
  • Location Wayne, PA, USA
  • Currency USD
  • Founded November 2011
  • Employees 2

Company Summary

NID's product is non-invasive, radiation free breast cancer diagnostic device that significantly lowers the risk of misdiagnosing the presence of breast cancer particularly at an early stage for younger women when intervention greatly improves survival rates.


  • Default avatar
    Richard Blumberg, Esq.

    1970: B.S. in Electrical Engineering and Computer Science, summa cum laude, University of Illinois.

    1973: J.D. Stanford University.

    1974-1978: Staff lawyer/Director Legal Services for institutionalized persons in the State of Washington.

    1978-present: Principal, Webster Mrak & Blumberg, medical-legal and class action labor litigation firm; judgments and verdicts exceeding $150 million.

    1993-present: Venture capital entrepreneur in hi

  • Default avatar
    Michael James Antonoplos
    COO, Secretary, Member, Board Member

    Michael Antonoplos is a 38 year veteran of the commercial real estate industry. He is a principal of a firm he started in 2000 which provides debt and equity for a variety of real estate investments. As a partner in a privately held real estate investment fund, Mr. Antonoplos was instrumental in raising and placing from the private sector over $70 million in real estate investment opportunities. During his career Mr. Antonoplos has secured ove

  • Default avatar
    Mark Faupel, Phd.

    Dr. Faupel is presently President and Chief Executive Officer of Guided Therapeutics, Inc. He has been a senior executive for innovative medical companies since 1986 when he co-founded Biofield Corp. Dr. Faupel joined Guided Therapeutics, Inc. (then SpectRx, Inc.) in 1998 as Vice President for Business Development and was promoted to Executive Vice President and Chief Technical Officer in 2001, where he coordinated R&D, Engineering, Clinical and

  • Default avatar
    Ronald W. Hart, Phd.

    Dr. Hart, identified the pivotal role of DNA damage in cancer and aging, is an internationally recognized scientist, scholar and expert in business acceleration strategies for emerging growth companies. He is the former Chief Scientist and Executive Director of the FDA’s National Center for Toxicology Research and was the first person in the history of the FDA to be named “distinguished scientist in residence.” In addition, he was a co-author of

  • Default avatar
    Robert E. Albus
    Financial Advisor to the Board

    In addition to his M&A experience, Bob provides a financial, corporate marketing and general management background to Goodrich Capital client companies. He has worked with Private Equity firms as a senior operating executive and Board advisor for the past five years. Prior to this he was President of Premier Inc, a consumer products company he founded and sold to Advanced Polymer Systems where he became President of the Toiletry Division.



  • Default avatar
    Michael Refolo
    Default avatar
    Charles Rufai

Previous Investors

  • Default avatar
    Rick Blumberg
    Default avatar
    Michael Antonoplos